Clinical trials: Pembrolizumab
Melanoma Stage Iii, Melanoma Stage Iv
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
This is a multicenter open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with an anti-Programmed death-1 or Programmed death ligand 1…
- Conditions
- Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin)
- Trial name
- NCT03620019
- Testing
- Denosumab, Pembrolizumab, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug.
- Conditions
- Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer
- Trial name
- NCT02661100
- Testing
- Pembrolizumab, CDX-1401, Poly-ICLC
- Sponsor
- Case Comprehensive Cancer Center
Gastric and Gastroesophageal Junction Adenocarcinoma
Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer
This is a two-part, Phase II, open-label, single arm, multi-center study to determine the efficacy of pembrolizumab in combination with TAS-102 (trifluridine/tipiracil) in patients with advanced gastric cancer who have progressed…
- Trial name
- NCT05508737
- Testing
- Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
- Where
- 2 sites in South Korea
- Volunteers
- 75 people
- Sponsor
- Yonsei University
Advanced Solid Tumor
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: Pembrolizumab AMG386
- Trial name
- NCT03239145
- Testing
- Pembrolizumab, Trebananib
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab.
- Trial name
- NCT06623422
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- 245 sites in United States, Argentina and 29 more
- Volunteers
- 680 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer Metastatic
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
This is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1…
- Trial name
- ANTELOPE (NCT05689671)
- Testing
- Atezolizumab, Nab paclitaxel, Carboplatin
- Where
- 36 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Nikolaj Frost MD
Esophageal Squamous Cell Carcinoma
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
In this study, participants with histologically diagnosed locally advanced esophageal squamous cell carcinoma who have received preoperative cisplatin-based chemoradiotherapy followed by surgery harbouring high risk of tumor…
- Trial name
- NCT03322267
- Testing
- Pembrolizumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Brain Cancer, Brain Neoplasm
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies.
- Conditions
- Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma
- Trial name
- CAPTIVE (NCT02798406)
- Testing
- DNX-2401, pembrolizumab
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- DNAtrix, Inc.
Carcinoma, Non-small-cell Lung, Mesothelioma
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
This study will explore whether defactinib (a FAK inhibitor) can be safely and tolerably combined with pembrolizumab (a PD-1 inhibitor) and will look for early indications of improved anticancer immunotherapy.
- Conditions
- Carcinoma, Non-small-cell Lung, Mesothelioma, Pancreatic Neoplasms
- Trial name
- NCT02758587
- Testing
- Defactinib, Pembrolizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 59 people
- Sponsor
- NHS Greater Glasgow and Clyde
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma
- Trial name
- NCT04708418
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 187 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Invasive Bladder Cancer
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
PLUMMB is an phase I trial to investigate the safety, tolerability and effectiveness of an immunotherapy drug called Pembrolizumab used in combination with radiotherapy.
- Trial name
- PLUMMB (NCT02560636)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- United Kingdom
- Volunteers
- 34 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Ovarian Cancer
Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer
French multicenter, open-label, phase 1b, evaluating via the mTPI design the paired treatment of pembrolizumab and PLD (cohort A), pembrolizumab and bevacizumab (cohort B) and finally the combination treatment of the three drugs…
- Trial name
- PEMBOV (NCT03596281)
- Testing
- Pembrolizumab, Bevacizumab, pegylated liposomal doxorubicin (PLD)
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Biliary Tract Cancer (BTC)
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract Cancer
The purpose of this study is to explore the effects of sacituzumab tirumotecan combined with pembrolizumab on survival, disease progression, and safety in patients with advanced biliary tract malignancies in the second-line and…
- Trial name
- NCT07850791
- Testing
- Sacituzumab Tirumotecan (SKB264), Pembrolizumab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Haitao Zhao, MD
Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma
To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA treated with neoadjuvant pembrolizumab followed by surgical resection.
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04089904
- Testing
- Pembrolizumab Injection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Squamous Cell Carcinoma of the Head and Neck
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
A small group of skin cancers of the head and neck, called resected cutaneous squamous carcinomas, are more aggressive than most cancers of this type, even after being treated with standard therapy.
- Trial name
- NCT03057613
- Testing
- Pembrolizumab, IMRT 60-66Gy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Case Comprehensive Cancer Center
Brain Metastases
Pembrolizumab In Central Nervous System Metastases
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
- Trial name
- NCT02886585
- Testing
- Pembrolizumab, MRI, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Massachusetts General Hospital
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
To look at the effectiveness of the combination of pembrolizumab, carboplatin, and paclitaxel in participants with stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer.
- Trial name
- NCT06318897
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Endometrial Cancer
Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a…
- Trial name
- NCT07594015
- Testing
- Pembrolizumab, Lenvatinib
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Miami
Hodgkin Lymphoma
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and…
- Trial name
- NCT02665650
- Testing
- AFM13, Pembrolizumab
- Where
- 18 sites in United States, Spain
- Volunteers
- 30 people
- Sponsor
- Affimed GmbH
Melanoma Metastatic, Melanoma Recurrent
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
The OTIMAS study is a phase II trial designed to evaluate if the duration of one year of pembrolizumab immunotherapy for advanced metastatic melanoma has equivalent efficacy as the two-year duration of historical controls.
- Conditions
- Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma, Stage IV Melanoma
- Trial name
- OTIMAS (NCT07376317)
- Testing
- Pembrolizumab
- Where
- Brazil
- Volunteers
- 29 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.